CAR-T cell therapy research

This study identifies two distinct waves of CD8+ CAR T-cell differentiation in DLBCL patients, showing they originate from different precursor populations with distinct phenotypes and ontogenies.

This study shows that aging affects CAR T cell production and function, leading to reduced therapeutic efficacy in elderly hosts.

This study enhances CAR-NK cell functionality using non-viral base editing and transposon integration, showing improved therapeutic potential in Burkitt's lymphoma models.

makeTCR provides a modular platform for rapid, scalable, single-step TCR synthesis and validation, enabling functional testing within 48 hours.

This study identifies IKAROS as a factor associated with antigen escape in B-ALL, showing that low IKAROS levels lead to reduced B-cell antigen expression and resistance to CD19- and CD22-targeted therapies.

This study develops lentiviral vectors with improved specificity and reduced immune clearance for in vivo CAR T cell generation, showing efficacy in a preclinical model.

This study shows that IL-18 enhances antitumor activity of CAR-NKT cells against neuroblastoma by promoting metabolic reprogramming and reducing exhaustion markers.

This study develops a fully human CAR-T cell therapy targeting the STn antigen, showing activity in preclinical models of gastro-intestinal and gynecological cancers.

The paper develops a mathematical model to analyze the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome, identifying key mechanisms and parameters influencing treatment outcomes.

This study shows that γδT cells can selectively kill medulloblastoma cells without harming neurons or stem cells, offering a safer and more effective treatment option.

This study engineers CAR T cells with PDL1-IL12 fusion proteins to enhance anti-tumor responses in solid tumors by improving T cell function and reducing systemic inflammation.

This paper introduces cysteine-engineered CAR-T cells that target both conventional antigens and altered redox states in B cell lymphoma, reducing the risk of antigen escape.

This study characterizes CAR+ T-cell subsets and immune system dynamics in pediatric BCP-ALL patients treated with tisagenlecleucel, finding correlations between immune cell changes and cytokine release syndrome.

This paper introduces LogiCAR designer, a computational method using single-cell transcriptomics to identify logic-gated antigen combinations for CAR therapy, showing improved efficacy and safety compared to existing approaches.

This study shows that total body irradiation before CAR T cell infusion enhances their effectiveness against large B-cell lymphoma by improving cytotoxicity and survival outcomes.

The paper introduces maRQup, a method for analyzing bioluminescent tumor images in over 1,000 mice, showing CD28 CAR-T cells initially control tumors better than 4-1BB CAR-T cells, which reduce relapse frequency.

The paper identifies T-cell receptors targeting KRAS Q61H neoantigen in NSCLC patients using antigen-agnostic screening and demonstrates their reactivity and potential for adoptive cell therapy.

This paper develops T-SenSER, a synthetic biosensor for T cells that enhances anti-tumor responses by sensing TME factors like VEGF and CSF1, showing improved efficacy in lung cancer and multiple myeloma models.

This study engineers CSPG4-targeting CAR-macrophages that inhibit melanoma growth in vitro and in vivo, showing promise for solid tumor immunotherapy.

This study improves the in vivo efficacy of CD22-targeted CAR T cells by optimizing the balance between binding affinity and tonic signaling through rational redesign of the antigen binding domain.

This paper develops a method to reduce TCR expression in CAR T cells using engineered CD3 subunits with an endoplasmic reticulum retention signal, avoiding genome editing and enabling safer allogeneic CAR T cell production.

This study identifies a Th1/Th17 imbalance driven by IFN{gamma} that causes cytokine release syndrome and neutropenia in CAR-T therapy, suggesting IFN{gamma} blockade as a potential treatment.

This study screens CAR-T designs in nonhuman primates and identifies MyD88-CD40 costimulatory domains as superior for proliferation, trafficking, and persistence.

This study identifies that the costimulatory domain of CD19-CAR-T cells influences resistance development in B-cell malignancies by affecting CD19 loss and antigen escape.

This paper proposes CAR-B cell therapy targeting anti-HLA Class I and II antibodies to reduce graft rejection and transfusion reactions by specifically neutralizing these antibodies and T cell responses.

This study introduces hydroporation as a scalable and efficient method for delivering CAR-T cells, achieving higher yields and viability compared to traditional methods.

The paper identifies combinatorial CAR signaling domains that enhance macrophage function and tumor clearance through pooled screening and single-cell analysis.

This study shows that varying CAR expression levels in T cells affects their activation, function, and transcriptional identity, with optimal CAR levels preventing exhaustion.

This paper develops a PDPN- and GD2-targeting CAR T cell blend to overcome glioblastoma heterogeneity, showing improved anti-tumor activity in organoids and increased survival in mice.